About the Company
Jay M. Short is founder and CEO of the antibody drug company BioAtla, LLC. He was vice president of research and operations at Stratagene (now Agilent Technologies), president of the Stratagene antibody subsidiary Stratacyte, then founder and CEO of Diversa until 2005. While at Diversa, Short invented methods of protein and pathway discovery via metagenomics, in addition to evolution technologies gene site saturation mutagenesis (GSSM) and GeneReassembly, and was the first to combine these discovery and evolution technologies. On December 7, 2015, San Diego–based BioAtla signed a license and option deal with Pfizer, involving BioAtla's conditionally-active biologics (CAB) antibody platform and Pfizer's antibody-drug conjugate (ADC) payloads. BioAtla is eligible to receive more than $1.0 billion in up-front, regulatory and sales milestone commitments as well as tiered marginal royalties reaching double digits on potential future product sales. Short is also founder of the E. O. Wilson Biodiversity Foundation, chairman of the board of Ciris Energy, and member of the board of directors of Senomyx. Short received his Ph.D. in biochemistry from Case Western Reserve University in Cleveland, Ohio, and his B.A. with honors in chemistry from Taylor University in Upland, Indiana.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on BioAtla, Inc.
BioAtla, Inc. (NASDAQ:BCAB) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 9, 2025 Operator: Good day, everyone, and welcome to the BioAtla Second Quarter 2025 ...
BioAtla’s Earnings Call: Positive Clinical Progress Amid Financial Challenges
Bioatla, Inc. (($BCAB)) has held its Q2 earnings call. Read on for the main highlights of the call. BioAtla, Inc. recently held its earnings call, ...
BioAtla, Inc. Announces Abstract Presentations at European ... - Nasdaq
BioAtla, Inc. announced it will present two posters at upcoming cancer conferences, the European Lung Cancer Congress and the Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium, both ...
BioAtla and Context Therapeutics Announce Exclusive Worldwide License ...
BioAtla maintains an FDA-cleared IND for its next-gen CAB-Nectin4-ADC, BA3361, the Company’s first glycoconjugate. To learn more about BioAtla, Inc. visit www.bioatla.com.
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study ongoing; ...
BioAtla Announces FDA Clearance of Investigational ... - Markets Insider
About BioAtla®, Inc. BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro ...
BioAtla Announces Upcoming Oral Presentation at the 2025 European ...
SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of ...
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid ...
About BioAtla®, Inc. BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro ...
BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ETCompany ParticipantsBruce Mackle - Investor Relations, LifeSci ...
Bioatla Inc. (BCAB) - News - Insider Monkey
BioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Call Transcript Operator: Good afternoon, ladies and gentlemen, and welcome to the BioAtla Third Quarter 2023 Earnings Call.
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid ...
SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the development of ...
Similar Companies
Loading the latest forecasts...